SAN FRANCISCO — Vision gains achieved in the first year of the CEDAR and SEQUOIA studies were maintained in the second year with only four treatments of abicipar intravitreal injections, comparable to results achievable with monthly ranibizumab treatment, according to a speaker.
“The improvements in visual acuity and retinal thickness were maintained through week 104 and were similar for abicipar every 12 weeks vs. ranibizumab every 4 weeks: 10 injections over 2 years vs. 25 injections,” Rahul N. Khurana, MD, said at Retina Subspecialty Day at the American Academy of
Uncategorized